Clinical Trial Update: Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating combination chemotherapy with or without interleukin-2 and interferon alfa in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Melanoma (Skin) | Phase 3 | Status: COMPLETED